{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:35:01Z","timestamp":1780392901097,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,8,29]],"date-time":"2006-08-29T00:00:00Z","timestamp":1156809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2007,2,5]]},"DOI":"10.1007\/s00520-006-0120-z","type":"journal-article","created":{"date-parts":[[2006,8,28]],"date-time":"2006-08-28T10:05:52Z","timestamp":1156759552000},"page":"197-202","source":"Crossref","is-referenced-by-count":70,"title":["Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Christian","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut A.","family":"Gr\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Al-Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,8,29]]},"reference":[{"key":"120_CR1","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961\u20132978","journal-title":"Cancer"},{"key":"120_CR2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","volume":"4","author":"H Fleisch","year":"2002","unstructured":"Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4:30\u201334","journal-title":"Breast Cancer Res"},{"key":"120_CR3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Pluijm van der","year":"1996","unstructured":"van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698\u2013705","journal-title":"J Clin Invest"},{"key":"120_CR4","first-page":"3890","volume":"57","author":"S Boissier","year":"1997","unstructured":"Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890\u20133894","journal-title":"Cancer Res"},{"key":"120_CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/0929867033368529","volume":"10","author":"P Clezardin","year":"2003","unstructured":"Clezardin P, Fournier P, Boissier S, Peyruchaud O (2003) In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10:173\u2013180","journal-title":"Curr Med Chem"},{"key":"120_CR6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385","journal-title":"Bone"},{"key":"120_CR7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2165\/00003495-200464110-00004","volume":"64","author":"CM Perry","year":"2004","unstructured":"Perry CM, Figgitt DP (2004) Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64:1197\u20131211","journal-title":"Drugs"},{"key":"120_CR8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jnci\/84.10.788","volume":"84","author":"S Leyvraz","year":"1992","unstructured":"Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P (1992) Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84:788\u2013792","journal-title":"J Natl Cancer Inst"},{"key":"120_CR9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","volume":"33","author":"D Amin","year":"1992","unstructured":"Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657\u20131663","journal-title":"J Lipid Res"},{"key":"120_CR10","first-page":"759","volume":"46","author":"D Amin","year":"1996","unstructured":"Amin D, Cornell SA, Perrone MH, Bilder GE (1996) 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung 46:759\u2013762","journal-title":"Arzneimittelforschung"},{"key":"120_CR11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"120_CR12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1834-7819.2003.tb00015.x","volume":"48","author":"GD Carter","year":"2003","unstructured":"Carter GD, Goss AN (2003) Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48:268","journal-title":"Aust Dent J"},{"key":"120_CR13","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","volume":"21","author":"CA Migliorati","year":"2003","unstructured":"Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253\u20134254","journal-title":"J Clin Oncol"},{"key":"120_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"120_CR15","first-page":"52","volume":"8","author":"KA Gr\u00f6tz","year":"2005","unstructured":"Gr\u00f6tz KA, Diel IJ (2005) Osteonekrose des Kiefers unter Bisphosphonat Langzeittherapie. Im Focus Onkologie 8:52\u201355","journal-title":"Im Focus Onkologie"},{"key":"120_CR16","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538\u20136544","journal-title":"Cancer Res"},{"key":"120_CR17","first-page":"1080","volume":"8","author":"D Santini","year":"2002","unstructured":"Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080\u20131084","journal-title":"Clin Cancer Res"},{"key":"120_CR18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055\u20131061","journal-title":"J Pharmacol Exp Ther"},{"key":"120_CR19","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478\u20131487","journal-title":"J Bone Miner Res"},{"key":"120_CR20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","volume":"19","author":"B Pan","year":"2004","unstructured":"Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147\u2013154","journal-title":"J Bone Miner Res"},{"key":"120_CR21","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","volume":"280","author":"LI Plotkin","year":"2005","unstructured":"Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317\u20137325","journal-title":"J Biol Chem"},{"key":"120_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","volume":"35","author":"T Hansen","year":"2006","unstructured":"Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155\u2013160","journal-title":"J Oral Pathol Med"},{"key":"120_CR23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/bmj.2.2013.270-a","volume":"2","author":"WF Dearden","year":"1899","unstructured":"Dearden WF (1899) Fragilitas ossium amongst workers in Lucifer match factories. BMJ 2:270","journal-title":"BMJ"},{"key":"120_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2004.08.001","volume":"53","author":"D Bernardi","year":"2005","unstructured":"Bernardi D, Barzan L, Franchin G, Cinelli R, Balestreri L, Tirelli U, Vaccher E (2005) Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Crit Rev Oncol Hematol 53:71\u201380","journal-title":"Crit Rev Oncol Hematol"},{"key":"120_CR25","first-page":"135","volume":"13","author":"AG Macdonald","year":"2001","unstructured":"Macdonald AG, Bissett JD (2001) Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. Clin Oncol (R Coll Radiol) 13:135\u2013137","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"120_CR26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/brst.2000.0239","volume":"10","author":"LK Dawson","year":"2001","unstructured":"Dawson LK, Nussey F, Oliver TB, Marks RC, Leonard RC (2001) Osteonecrosis of the femoral head following adjuvant chemotherapy for breast cancer. Breast 10:447\u2013449","journal-title":"Breast"},{"key":"120_CR27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","volume":"61","author":"P Tarassoff","year":"2003","unstructured":"Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61:1238\u20131239","journal-title":"J Oral Maxillofac Surg"},{"key":"120_CR28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0022-3913(88)90015-7","volume":"59","author":"EV Kluth","year":"1988","unstructured":"Kluth EV, Jain PR, Stuchell RN, Frich JC Jr (1988) A study of factors contributing to the development of osteoradionecrosis of the jaws. J Prosthet Dent 59:194\u2013201","journal-title":"J Prosthet Dent"},{"key":"120_CR29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0278-2391(97)90478-X","volume":"55","author":"MM Curi","year":"1997","unstructured":"Curi MM, Dib LL (1997) Osteoradionecrosis of the jaws: a retrospective study of the background factors and treatment in 104 cases. J Oral Maxillofac Surg 55:540\u2013544 (Discussion 545\u2013546)","journal-title":"J Oral Maxillofac Surg"},{"key":"120_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/ijom.2002.0332","volume":"32","author":"T Reuther","year":"2003","unstructured":"Reuther T, Schuster T, Mende U, Kubler A (2003) Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients-a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 32:289\u2013295","journal-title":"Int J Oral Maxillofac Surg"},{"key":"120_CR31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.47102\/annals-acadmedsg.V33N4p48S","volume":"33","author":"NA Robinson","year":"2004","unstructured":"Robinson NA, Yeo JF (2004) Bisphosphonates-a word of caution. Ann Acad Med Singapore 33:48\u201349","journal-title":"Ann Acad Med Singapore"},{"key":"120_CR32","first-page":"440","volume":"41","author":"W Wagner","year":"1986","unstructured":"Wagner W, Kuffner HD, Hartmann U (1986) Der bestrahlte Patient als Risikopatient bei zahn\u00e4rztlich\u2014chirurgischen Eingriffen. Dtsch Zahnarztl Z 41:440\u2013443","journal-title":"Dtsch Zahnarztl Z"},{"key":"120_CR33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0305-7372(03)00013-6","volume":"29","author":"PJ Hoskin","year":"2003","unstructured":"Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321\u2013327","journal-title":"Cancer Treat Rev"},{"key":"120_CR34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijrobp.2004.09.065","volume":"61","author":"E Algur","year":"2005","unstructured":"Algur E, Macklis RM, Hafeli UO (2005) Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61:535\u2013542","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"120_CR35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.joms.2004.03.005","volume":"62","author":"HC Schwartz","year":"2004","unstructured":"Schwartz HC (2004) Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 62:763\u2013764","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-006-0120-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-006-0120-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-006-0120-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T05:16:31Z","timestamp":1707196591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-006-0120-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,29]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2,5]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1007\/s00520-006-0120-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,29]]}}}